difficult to differentiate lethal from more indolent forms of the disease. [2] [3] [4] [5] [6] Frequent copy number alterations are found during prostate cancer carcinogenesis including loss of chromosome 8p (NKX3.1), amplification of 8q24 (MYC), and deletion of PTEN on chromosome 10q23. [7] [8] [9] Loss of PTEN occurs in approximately 50% of lethal prostate cancers and has been shown in multiple studies to be linked to disease aggressiveness and prostate cancer specific death. [10] [11] [12] [13] [14] [15] Similarly, amplification of the MYC locus has been correlated with poor outcomes and disease recurrence after prostatectomy. [16] [17] [18] Patients whose tumors harbored concurrent MYC amplification and PTEN loss were at increased the risk of prostate cancer specific mortality suggesting that the combination of both genetic events may cooperatively drive aggressive disease. 19 The development of mouse models which recapitulate human prostate cancer has been limited due to absence of metastatic disease, atypical histologic features (ie, neuroendocrine or sarcomatoid phenotype), lack of genomic instability, or the use of driver genes rarely altered genetically in human prostate cancer. 20, 21 In prior studies, loss of both
Pten alleles or activation of MYC alone in the mouse prostate resulted in PIN and early invasive carcinoma with rare instances of metastatic disease. 20 In the Z-MYC model, prostate-specific overexpression of MYC resulted in low-grade PIN, but invasive carcinomas were observed only upon deletion of one or both Pten alleles suggestive of a potential cooperative effect of Pten loss and MYC activation. 22 This genetically engineered model did not result in widespread metastatic disease and genetic instability was not examined.
Recently, our group developed a mouse model (referred to as BMPC) that undergoes forced overexpression of MYC and deletion of both copies of Pten in the mouse prostate using Hoxb13 transcriptional control elements. 23 These mice invariably develop lethal metastatic castration resistant prostatic adenocarcinomas that recapitulate key histopathologic and phenotypic (eg, activation of Akt) features of human prostate cancer initiation and progression. 23 In BMPC mice, metastatic sites of disease include lymph node involvement, with less frequent lung, and liver dissemination. Although very rare, bone metastases have also been observed, similar to human prostate cancer.
Importantly, the prostate cancers that develop in the BMPC mice have widespread genome copy number alterations, a feature that is reminiscent of human disease, and not recapitulated in most other well-studied prostate cancer mouse models. [23] [24] [25] [26] [27] For instance, one of the only other mouse models demonstrating genomic instability required forced telomere shortening in the context of Tp53 and Pten deletion. 28 However, mice with combined Tp53 and Pten deletion commonly develop invasive prostatic tumors with sarcomatoid differentiation rather than adenocarcinoma. 20 The primary and metastatic carcinomas in the BMPC mice lack both neuroendocrine and sarcomatoid differentiation, features uncommon in untreated, human prostate cancers. The use of commonly altered driver genes in the human disease, the kinetics of disease initiation and progression, the metastases to relevant physiological sites, and the emergence of genetic instability in this model provide an opportunity to test new therapeutic strategies to prevent and treat lethal forms of human prostate cancer. 23 To extend the utility of the BMPC model, in the present study we generated two mouse cell lines (BMPC1 
| RNA in situ hybridization
Chromogenic RNA in situ hybridization was performed by using ACD O.D. = 3.18 mm) and the tubing was sealed using medical grade adhesive.
Mice were anesthetized using intraperitoneal injection with Avertin.
Once deep anesthesia had been achieved, a 5 mm incision was made perpendicular to the dorsal midline at the cervico-thoracic junction.
Using blunt scissors, the skin and fascia were gently dissected from the underlying muscle to create a ∼2 cm pocket extending posteriorly along the dorsal midline. Using sterile forceps, the silastic tubing was inserted into the subcutaneous pocket, and the incision was closed with 6-0 nylon suture. Animals were placed in a cage on a heating pad and monitored until they were ambulatory. The animals were then returned to the animal facility where they remained till the end of the study. For sham castration the same procedure was performed but the testicles were not removed. Animals were placed in a cage on a heating pad and monitored until they were ambulatory. The animals were provided with ibuprofen in drinking water for 48 h for post-operative analgesia.
| RESULTS
Each cell line was initially characterized for phenotype using immunohistochemistry (IHC) and RNA in situ hybridization (RNAish) ( Figures 1A and 1B Figure 1A , Figure 2C ) and was undetectable in BMPC2 Figure 1C .
Additional whole genomic characterizations will be presented separately.
We then further characterized AR expression and androgen responsiveness in both cell lines. Although AR protein was observed in BMPC1 cells at low levels via IHC, a band corresponding to the correct size of AR was not detected by western blot (Figure 2A Given the effect of R1881 on AR protein levels in BMPC1, we examined the effect of both R1881 supplementation and anti-androgen treatment in a series of in vitro growth experiments. We examined the cell growth of both BMPC1 and BMPC2 in the presence and absence of the anti-androgen, enzalutamide ( Figure 3A ). BMPC1 and BMPC2 cell growth was not affected by the addition of enzalutamide, 
| DISCUSSION
BMPC1 and BMPC2 cell lines were generated in a mouse model reliant on Hoxb13 transcriptional control elements, which direct gene expression in the prostate, and distal large intestine/rectum. 31 We confirmed the prostatic origin of both lines via detection of the prostate-specific homeodomain protein, Nkx3.1, as well as AR mRNA.
In comparison to MYC-CaP cells, BMPC1 had significantly less AR mRNA and BMPC2 was negative by in situ hybridization, and slightly positive by RT-PCR. Whereas AR protein expression in BMPC2 was absent, BMPC1 make low levels of AR under normal growth We explored whether manipulating androgen levels would affect AR expression in these cell lines. Media supplemented with charcoal stripped media (ie, androgen depleted) resulted in increased AR mRNA in the BMPC1 cell line suggesting a negative, autoregulation of AR expression. Despite an increase in mRNA, no change in AR protein was observed. AR protein has been shown to be more stable in the presence of ligand prompting further investigation of the role of androgens on the posttranslational regulation of AR protein. 35 The addition of a synthetic androgen (R1881) increased the level of AR protein and resulted in nuclear localization in only the BMPC1 Line. We did not measure circulating testosterone levels in the intact, castrated, or DHT-supplemented mice which is an acknowledged weakness of this study. However, we speculate that circulating levels of androgens in the mouse models may not be sufficient to stabilize AR protein contributing to this loss. This hypothesis is supported by our in vivo data, which showed increased/stable AR protein levels in BMPC1
allografts following the implantation of DHT without a corresponding increase in mRNA. Castration of these mice lead to an increase in BMPC1 AR mRNA, but not protein, consistent with the in vitro findings. Testosterone levels in mice are decreased in the presence of disease states such as cancer, suggesting a possible mechanism for diminished AR expression in the BMPC, and other mouse models of prostate cancer. 36 In the absence of androgen in hormone sensitive prostate cancer cells (ie, LNCaP), AR protein is unstable leading to decreased levels, which is consistent with the BMPC1 in vitro model. 37 Although AR protein can be stabilized and translocated to the nucleus, BMPC1 cell growth was not affected by the presence of R1881 or treatment with an anti-androgen. We also did not observe a change in Nkx3.1 mRNA or protein levels in both the in vitro and in vivo experimental system in the presence of androgens. This suggests that AR, although present, is not transcriptionally active and/or significantly affecting cell growth. The mechanism for this phenomenon is unclear and may be related to the low levels of AR mRNA and protein at baseline. The term "androgen indifferent" prostate cancer has been coined by Aparicio and colleagues to describe a variant of prostate adenocarcinoma. This subtype of prostate cancer is characterized, in part, by absent or low levels of AR protein. 38 Such cancers typically have a short duration of response to hormonal therapies and may benefit from platinum based chemotherapy.
39
BMPC1 and BMPC2 may model AR-indifferent prostate cancer as demonstrated by a lack of sensitivity to androgen stimulation as well as exposure to an anti-androgen. These cell lines may then serve as an in vitro tool for further study of a lethal subtype of prostate adenocarcinoma.
